<?xml version="1.0" encoding="UTF-8"?>
<p id="para3420">Licensed versions of several direct-acting antiviral drugs with anti-HCV activity (including sofosbuvir, daclatasvir, sofosbuvir–ledipasvir, and sofosbuvir–velpatasvir) are available in India, and the price for a course of 3–6 months at the Government's expense is about $1 a day. A modelling study showed that treatment of HCV infection using generic direct-acting antiviral drugs is cost-saving.
 <xref rid="bib402" ref-type="bibr">
  <sup>402</sup>
 </xref> Provision of HBV oral drugs through the National Viral Hepatitis Control Program is currently in the planning stage.
</p>
